Protocol: Analytical Method Validation (HPLC Assay and Related Substances)

This is a ready-to-use analytical method validation protocol for a reverse-phase HPLC method that reports both assay and related substances. Replace every <<FILL: ...>> placeholder with your own specifics, set your document numbers and dates, and route it through document control for approval before any validation data are generated. A worked filled specimen follows so you can see how a completed characteristic reads. Confirm each cited chapter and guideline against the current source before you rely on it. This is general educational content to adapt to your product, method, and quality system, not regulatory advice.

Approval page

Approve this protocol before executing any study. The signatures below record that the design and, above all, the acceptance criteria were fixed before data existed.

Document control header

1. Objective

To demonstrate, with documented evidence, that the HPLC method <<FILL: method number>> is fit for its intended use: the quantitative determination of <<FILL: analyte>> assay and the quantitation and identification of related substances in <<FILL: product>>. The validation establishes the performance characteristics required by ICH Q2(R2) for a quantitative assay and impurity method, against acceptance criteria pre-defined in this protocol.

2. Scope

This protocol covers validation of the method for <<FILL: matrix / dosage form>> at the laboratory named in the header. It addresses specificity, accuracy, precision (repeatability and intermediate precision), linearity, range, limit of quantitation and detection for related substances, solution stability, filter validation, and robustness. Reproducibility across laboratories is out of scope and is handled by method transfer where applicable. Compendial verification, if the method is pharmacopeial, is out of scope and follows the verification procedure instead.

3. Method description

4. Prerequisites

Confirm and record each before execution. A study run on an unqualified instrument or by an untrained analyst is not usable evidence.

• The instrument holds current qualification (DQ/IQ/OQ, and PQ where applicable); record the qualification reference.
• Analysts are trained on the method and this protocol; record training references.
• The reference standard is qualified, in date, and its assigned value and traceability are documented.
• Reagents, columns, and consumables are recorded by lot.
• The chromatography data system is validated, its audit trail is enabled, and access is controlled.
• This protocol is approved (approval page signed) before any validation data are acquired.

5. Responsibilities

6. System suitability

Before each validation sequence, confirm system suitability against criteria derived from method development. Recommended defaults, to be finalized in the header of each study:

If system suitability fails, the sequence is invalid and its data are not used.

7. Validation studies, designs, and acceptance criteria

Each study below lists the design, the pre-defined acceptance criterion, and a result table to complete. Record actual results, calculate, and record pass or fail.

7.1 Specificity

Design. Inject blank (diluent), placebo, unspiked sample, and sample spiked with known related substances. Run forced degradation (acid, base, oxidation, heat, and photolysis per ICH Q1B), targeting roughly 5 to 20 percent degradation. Apply peak purity (PDA or MS) on the main peak and confirm mass balance.

Acceptance criteria. No interference at the analyte or impurity retention times from blank or placebo. Resolution not less than <<FILL: 1.5-2.0>> between the analyte and the nearest peak. Peak purity within the platform threshold, for example a purity index above <<FILL: 0.99>>. Mass balance within <<FILL: plus or minus 5>> percent for stressed samples.

7.2 Accuracy

Design. Assay: spike reference standard into placebo at 80, 100, and 120 percent of label claim, three independent preparations per level (nine determinations). Impurities: spike each specified impurity into the matrix at the LOQ, the specification limit, and 120 percent of the limit, three preparations per level. Weigh each preparation independently.

Acceptance criteria. Assay mean recovery <<FILL: 98.0-102.0>> percent with RSD not more than <<FILL: 2.0>> percent. Impurity mean recovery <<FILL: 90-110>> percent near the specification level, wider near the LOQ per the study design.

7.3 Precision

Repeatability. Six independent sample preparations under one set of conditions. Intermediate precision. A minimum of two analysts on two days, varying instrument, column lot, and reagent lot where feasible, six preparations each. Report intermediate precision RSD from the pooled data set, not an average of daily RSDs.

Acceptance criteria. Repeatability RSD not more than <<FILL: 2.0>> percent. Intermediate precision pooled RSD not more than <<FILL: 2.0 (assay) / value (impurity)>> percent.

7.4 Linearity and range

Design. Prepare <<FILL: 5-7>> concentration levels from independent dilutions across <<FILL: assay range, e.g. 50-150%>> and, for impurities, from the LOQ to 120 percent of the specification limit. Fit linear regression; inspect the residual plot.

Acceptance criteria. Correlation coefficient not less than <<FILL: 0.999 (assay)>>, residuals randomly scattered around zero (no curvature), y-intercept small relative to the 100 percent response. Range is the interval over which accuracy, precision, and linearity are all demonstrated.

7.5 Limit of quantitation and detection (related substances)

Design. Estimate LOQ and LOD by signal-to-noise or the standard-deviation-and-slope approach, then confirm by injecting <<FILL: 6>> independent preparations at the estimated LOQ.

Acceptance criteria. Confirmed LOQ with recovery <<FILL: 80-120>> percent and RSD not more than <<FILL: 10>> percent, with the LOQ below the reporting threshold. LOD detectable with S/N not less than <<FILL: 3>>.

7.6 Solution stability

Design. Store standard and sample solutions under the intended conditions (bench, refrigerated, autosampler tray). Reinject against a freshly prepared reference at intervals bracketing the longest routine sequence.

Acceptance criteria. Aged solution recovers within <<FILL: 2.0>> percent of fresh for the assay, with no new peak above the reporting threshold. State the solution use period from the last passing interval.

7.7 Filter validation

Design. Compare filtered preparation against a centrifuged or inert-membrane reference across the discard-volume scheme.

Acceptance criteria. Filtered recovery within <<FILL: 2.0>> percent of the unfiltered reference, no leachable peak above the reporting threshold. State the discard volume that achieves full recovery.

7.8 Robustness

Design. Vary each parameter independently around the method setpoint (or run a designed experiment): mobile phase pH plus or minus 0.2, organic content plus or minus 2 percent, column temperature plus or minus 5 degrees C, flow rate plus or minus 10 percent, and a different column lot. Evaluate the effect on resolution, tailing, retention, and result.

Acceptance criteria. System suitability and quantitative result remain within limits across the studied variations, or the sensitive parameter is constrained in the method and reflected in system suitability.

8. Deviation handling

Any departure from this protocol, and any result that fails an acceptance criterion, is recorded as a protocol deviation with the detail, the cause where known, and an assessment of impact on the validation conclusion. Deviations are routed per <<FILL: SOP-ID for deviations>> and resolved before the report is approved. A study characteristic that fails is investigated; the method is not quietly re-optimized to pass after the criterion was set.

9. Summary and conclusion

On completion, the results are compiled in the validation report <<FILL: report number>>. The method is concluded validated for its intended use only when every applicable characteristic meets its pre-defined acceptance criterion, or any deviation is justified and shown not to affect the conclusion. The report is approved by Quality Assurance and referenced in the analytical procedure and, where applicable, in CTD Module 3 (3.2.S.4.3 or 3.2.P.5.3).

10. Attachments

• Approved test method <<FILL: number and version>>
• Instrument qualification and CDS validation references
• Reference standard qualification record
• Raw data and chromatograms (or their controlled location)
• Deviation records, if any

11. References

ICH Q2(R2), Validation of Analytical Procedures. ICH Q14, Analytical Procedure Development. ICH Q1B, Photostability Testing (for the photolysis arm of forced degradation). 21 CFR 211.165(e) and 211.194(a)(2) (US cGMP for method suitability and laboratory records). USP General Chapter <1225>, Validation of Compendial Procedures, for the underlying characteristic definitions.

Confirm the current version and clause numbers of each reference before issue.

12. Revision history

Filled specimen

The following shows the accuracy study (section 7.2) completed for an illustrative tablet assay, so you can see the level of detail expected. The company, method, and numbers are illustrative; replace them with your own.

Method: Reverse-phase HPLC assay of Compound X tablets, method TM-QC-0142, PDA detection at 254 nm. Acceptance criterion: mean recovery 98.0 to 102.0 percent, RSD not more than 2.0 percent.

Result: Mean recovery 99.8 percent, RSD 0.9 percent. Both within criteria. Pass. The spike was into placebo, not into product, so the true added amount is known; each of the nine preparations was weighed independently, so the replication is real rather than one weighing counted nine times. Those two design choices are what make the recovery defensible.

Common inspection findings this protocol prevents

• Acceptance criteria set or adjusted after the data were seen, which reads as a data integrity problem, not a technical one.
• A method called stability indicating with no forced degradation showing degradants resolve from the parent.
• Intermediate precision run by one analyst on one day, so the variability QC actually sees was never measured.
• LOQ calculated but never confirmed, or set at or above the reporting threshold.
• Linearity claimed on the correlation coefficient alone, with no residual plot.
• Solution stability and filter validation skipped, then routine failures traced to a degrading solution or an adsorbing filter.
• Validation run on an unqualified instrument or against a reference standard with undocumented traceability.

How to adapt this protocol

1. Set your protocol number, method reference, and product in the header, and get the approval page signed before any data.
2. Replace the method description and the specification limits in section 3 with your real method.
3. Set each acceptance criterion in section 7 from the method’s intended use and the width of your specification, not from the generic defaults shown.
4. Drop characteristics that do not apply to your method type (for example, a limit test needs only specificity and LOD) and record the rationale for each exclusion.
5. Point the deviation cross-reference in section 8 to your real procedure, and confirm every reference in section 11 against the current source.